Evaluation of genetic polymorphisms related to thrombophilia in patients with stroke in the Turkish population: A case-control study

Document Type : Original Article

Authors

1 Department of Neurology, School of Medicine, Necmettin Erbakan University, Konya, Turkey

2 Department of Medical Genetics, School of Medicine, Necmettin Erbakan University, Konya, Turkey

Abstract
Background: This study investigates the association between thrombophilia-related genetic variations and ischemic stroke risk in a Turkish population.
Methods: This study included 200 patients with ischemic stroke and 90 controls. Etiologies were classified using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) and Atherosclerosis, Small vessel disease, Cardiac source, Other cause (ASCO) criteria. Genetic analysis screened for methylenetetrahydrofolate reductase (MTHFR), factor V (FV), factor II, factor XIII, fibrinogen beta (FGB), integrin beta-3 (ITGB3), angiotensin-converting enzyme (ACE), angiotensinogen (AGT), angiotensin II receptor type 1 (AGTR1), endothelial nitric oxide synthase (NOS3), plasminogen activator inhibitor-1 (PAI-1), and protein C receptor (PROCR) variants using multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS).
Results: The MTHFR A1298C polymorphism was found to have a significant association with ischemic stroke in the recessive model [odds ratio (OR): 3.45, 95% confidence interval (CI): 1.157–10.332; P = 0.026]. According to the ASCO and TOAST classifications, significant associations were also identified between MTHFR polymorphisms and the cardioembolic and small vessel disease subtypes. The ACE polymorphism showed a significant association with cardioembolic stroke in both the TOAST and ASCO classifications (OR: 3.4, 95% CI: 1.0–10.8; P = 0.037 and OR: 2.7, 95% CI: 1.0–7.6; P = 0.047, respectively).
Additionally, the NOS3 E298D polymorphism was associated with stroke risk in patients with hypertension (HTN), while the AGT M268T and NOS3 T-786C polymorphisms were linked to stroke risk in patients with coronary artery disease (CAD). No significant associations were observed for FV, factor II, factor XIII, PAI-1, PROCR, AGTR1, FGB, or ITGB3 variants.
Conclusion: MTHFR A1298C gene polymorphism was found to be significantly associated with increased stroke risk and stroke etiology.

Keywords

Subjects

  1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16(11): 877-97.
  2. Warlow CP. Epidemiology of stroke. Lancet 1998; 352 Suppl 3: Siii1-4.
  3. Donkor ES. Stroke in the 21(st) Century: A Snapshot of the Burden, Epidemiology, and Quality of Life. Stroke Res Treat 2018; 2018: 3238165.
  4. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747-57.
  5. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of stroke in the Netherlands: the impact of stroke services. Int J Technol Assess Health Care 2006; 22(4): 518-24.
  6. Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. Circ Res 2017; 120(3): 472-95.
  7. Anderson CD, Biffi A, Rost NS, Cortellini L, Furie KL, Rosand J. Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke 2010; 41(6): 1123-31.
  8. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1): 35-41.
  9. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009; 27(5): 502-8.
  10. Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke 2012; 43(12): 3161-7.
  11. Gökçal E, Niftaliyev E, Asil T. Etiological classification of ischemic stroke in young patients: a comparative study of TOAST, CCS, and ASCO. Acta Neurol Belg 2017; 117(3): 643-8.
  12. Dikmen M. Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) Enzyme and Its Association with Diseases. Med J Kocatepe 2004; 5(2): 9-16. [In Turkish].
  13. Son P, Lewis L. Hyperhomocysteinemia. Treasure Island, FL: StatPearls Publishing; 2026.
  14. Jin M, Wang N, Li X, Zhang H, Zhou J, Cong M, et al. Relationship between MTHFR C677T, homocysteine, and ischemic stroke in a large sample of the Han Chinese population. Medicine (Baltimore) 2022; 101(38): e30562.
  15. Chita DS, Tudor A, Christodorescu R, Buleu FN, Sosdean R, Deme SM, et al. MTHFR Gene Polymorphisms Prevalence and Cardiovascular Risk Factors Involved in Cardioembolic Stroke Type and Severity. Brain Sci 2020; 10(8): 476.
  16. Rutten-Jacobs LC, Traylor M, Adib-Samii P, Thijs V, Sudlow C, Rothwell PM, et al. Association of MTHFR C677T Genotype With Ischemic Stroke Is Confined to Cerebral Small Vessel Disease Subtype. Stroke 2016; 47(3): 646-51.
  17. Salem-Berrabah OB, Mrissa R, Machghoul S, Hamida AB, N'Siri B, Mazigh C, et al. Hyperhomocysteinemia, C677T MTHFR polymorphism and ischemic stroke in Tunisian patients. Tunis Med 2010; 88(9): 655-9.
  18. Mialovytska O, Nebor Y. Analysis of relationshıp between polymorphism of MTHFR (c677t), mthfr (a1298c), mtr (a2756g) genes in the development of ischemic stroke in young patients. Georgian Med News 2021; (319): 87-92.
  19. Huang LW, Li LL, Li J, Chen XR, Yu M. Association of the methylenetetrahydrofolate reductase (MTHFR) gene variant C677T with serum homocysteine levels and the severity of ischaemic stroke: a case-control study in the southwest of China. J Int Med Res 2022; 50(2): 3000605221081632.
  20. Dong X, Wang J, Wang G, Wang J, Wang L, Du Y. MTHFR A1298C gene polymorphism on stroke risk: an updated meta-analysis. Genes Environ 2021; 43(1): 40.
  21. Lam W, Moosavi L. Physiology, Factor V. Treasure Island (FL): StatPearls Publishing; 2026.
  22. Ardizzone A, Capra AP, Mondello S, Briuglia S, La Rosa MA, Campolo M, et al. H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. Genes (Basel) 2022; 13(6): 1019.
  23. Mohapatra AK, Todaro AM, Castoldi E. Factor V variants in bleeding and thrombosis. Res Pract Thromb Haemost 2024; 8(1): 102330.
  24. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85(6): 1504-8.
  25. Duran R, Biner B, Demir M, Celtik C, Karasalihoğlu S. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost 2005; 11(1): 83-8.
  26. Barnes C, Deveber G. Prothrombotic abnormalities in childhood ischaemic stroke. Thromb Res 2006; 118(1): 67-74.
  27. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146(6): 948-57.
  28. Anadure R, Christopher R, Nagaraja D, Narayanan C. A genetic study of Factor V Leiden (G1691A) mutation in young ischemic strokes with large vessel disease in a South Indian population. J Clin Neurosci 2017; 44: 346-52.
  29. Hamedani AG, Cole JW, Cheng Y, Sparks MJ, O'Connell JR, Stine OC, et al. Factor V leiden and ischemic stroke risk: the Genetics of Early Onset Stroke (GEOS) study. J Stroke Cerebrovasc Dis 2013; 22(4): 419-23.
  30. Hamedani AG, Cole JW, Mitchell BD, Kittner SJ. Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment. Stroke 2010; 41(8): 1599-603.
  31. Sarecka-Hujar B, Kopyta I, Skrzypek M, Sordyl J. Association Between the 20210G>A Prothrombin Gene Polymorphism and Arterial Ischemic Stroke in Children and Young Adults-Two Meta-analyses of 3586 Cases and 6440 Control Subjects in Total. Pediatr Neurol 2017; 69: 93-101.
  32. Poudel S, Zeb M, Kondapaneni V, Gutlapalli SD, Choudhari J, Sodiya OT, et al. Association of G20210A Prothrombin Gene Mutation and Cerebral Ischemic Stroke in Young Patients. Cureus 2020; 12(12): e11984.
  33. Rallidis LS, Politou M, Komporozos C, Panagiotakos DB, Belessi CI, Travlou A, et al. Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost 2008; 99(6): 1085-9.
  34. Kattula S, Bagoly Z, Tóth NK, Muszbek L, Wolberg AS. The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations. J Thromb Haemost 2020; 18(4): 885-94.
  35. Shemirani AH, Pongrácz E, Antalfi B, Adány R, Muszbek L. Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke. Thromb Res 2010; 126(2): 159-62.
  36. Shemirani AH, Antalfi B, Pongrácz E, Mezei ZA, Bereczky Z, Csiki Z. Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke. Blood Coagul Fibrinolysis 2014; 25(4): 364-8.
  37. Gu L, Liu W, Yan Y, Su L, Wu G, Liang B, et al. Influence of the β-fibrinogen-455G/A polymorphism on development of ischemic stroke and coronary heart disease. Thromb Res 2014; 133(6): 993-1005.
  38. Li CX, Sun LC, Wang YQ, Liu TT, Cai JR, Liu H, et al. The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis. Hum Genomics 2024; 18(1): 135.
  39. Floyd CN, Ellis BH, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One 2014; 9(7): e100239.
  40. Chen XD, Tian L, Li M, Jin W, Zhang HK, Zheng CF. Relationship between endothelial cell protein C receptor gene 6936A/G polymorphisms and deep venous thrombosis. Chin Med J (Engl) 2011; 124(1): 72-5.
  41. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103(4): 1311-8.
  42. Medina P, Navarro S, Corral J, Zorio E, Roldán V, Estellés A, et al. Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica 2008; 93(9): 1358-63.
  43. Medina P, Navarro S, Estellés A, Vayá A, Woodhams B, Mira Y, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004; 91(5): 905-11.
  44. Akhter M, Biswas A, Saxena R. Role of endothelial nitric oxide synthase gene in vascular diseases. East J Med 2009; 14(2): 46-50.
  45. MacLeod MJ, Dahiyat MT, Cumming A, Meiklejohn D, Shaw D, St Clair D. No association between Glu/Asp polymorphism of NOS3 gene and ischemic stroke. Neurology 1999; 53(2): 418-20.
  46. Anlıaçık S, Tokgöz S, Zamani AG, Yıldırım MS, İyisoy MS. Investigation of the relationship between ischemic stroke and endothelial nitric oxide synthase gene polymorphisms [G894T, intron 4 VNTR and T786C]. Turk J Med Sci 2019; 49(2): 589-94.
  47. Saluja A, Saraswathy KN, Thakur S, Margekar S, Goyal A, Dhamija RK. Endothelial Nitric Oxide Synthase (Glu298Asp) Polymorphism is Associated Significantly with Ischemic Stroke Presenting with Seizures and Altered Sensorium. Neurol India 2021; 69(3): 686-91.
  48. Salminen LE, Schofield PR, Pierce KD, Zhao Y, Luo X, Wang Y, et al. Neuromarkers of the common angiotensinogen polymorphism in healthy older adults: A comprehensive assessment of white matter integrity and cognition. Behav Brain Res 2016; 296: 85-93.
  49. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med 2008; 10(8): 560-74.
  50. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One 2012; 7(10): e46495.
  51. Karakus N, Yigit S, Basol N, Incealtin O. Dual effect of methylene-tetrahydrofolate reductase and angiotensinconverting enzyme gene polymorphisms on the risk of acute ischemic stroke. J Genet 2023; 102: 29.
  52. Krleza JL, Coen Herak D, Đakovic I, Vulin K, Roic G, Tripalo Batoš A, et al. Inherited Thrombophilia Associated With Ischemic Pediatric Stroke in Parent-Child Pairs. Pediatr Neurol 2023; 146: 119-28.
  53. Cramer SC, Parodi L, Moslemi Z, Braun RG, Aldridge CM, Shahbaba B, et al. Genetic Variation and Stroke Recovery: The STRONG Study. Stroke 2024; 55(8): 2094-102.
  54. Gogu AE, Motoc AG, Stroe AZ, Docu Axelerad A, Docu Axelerad D, Petrica L, et al. Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis. Metabolites 2021; 11(5): 266.
  55. Hu X, Zan X, Xie Z, Li Y, Lin S, Li H, et al. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility. Mol Neurobiol 2017; 54(1): 328-41.

Articles in Press, Accepted Manuscript
Available Online from 29 September 2026